Antibody Drug Conjugate Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022 - 2027

Report Code: HCR 0152 Report Format: PDF + Excel

Antibody Drug Conjugate Market Overview

Antibody Drug Conjugate Market size is estimated to reach $10.32 billion by 2027, growing at a CAGR of 14.7% during the forecast period 2022-2027. Antibody-Drug Conjugate indicates monoclonal antibodies conjugated to cytotoxic agents. It utilizes antibodies that are particular to tumor cell-surface proteins and therefore, possess tumor particularity and efficacy unattainable with conventional medications. Antibody-drug conjugate (ADC) refers to a biopharmaceutical product where monoclonal antibodies are connected to biologically effective medications (tiny molecules) shaping a conjugate. Antibody-drug conjugates or ADCs are a class of biopharmaceutical medications planned as a targeted therapy for healing cancer. Dissimilar to chemotherapy, ADCs are aimed to target and destroy tumor cells while sparing healthy cells.

The expanding population of the elderly is set to drive the Antibody Drug Conjugate Market. The increase in the population of the obese and the surging application of antibody-drug conjugate involving monoclonal antibodies are set to propel the growth of the Antibody Drug Conjugate Market during the forecast period 2022-2027. This represents the Antibody Drug Conjugate Industry Outlook.

Report Coverage

The report: Antibody Drug Conjugate Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Antibody Drug Conjugate Market.

By Product Type: Adcetris, Kadcyla, Others.

By Application: Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, Others.

By Geography: North America (the U.S, Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America), and Rest Of The World (Middle East, Africa).

Key Takeaways

  • Geographically, North America Antibody Drug Conjugate Market accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing predominance of cancer resulting in heightened awareness of cancer and the upsurge in the application of antibody-drug conjugate involving monoclonal antibodies amidst the population in the North American region.
  • Antibody Drug Conjugate Market growth is being driven by the rising pervasiveness of cancer, the surging application of antibody-drug conjugate involving monoclonal antibodies, and the surging R&D activities for the evolution of new therapeutics. However, the binding government regulations, the soaring cost of procedures, and the dearth of funds are some of the major factors hampering the growth of the Antibody Drug Conjugate Market. 
  • Antibody Drug Conjugate Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the  Antibody Drug Conjugate Market report 

Antibody Drug Conjugate Market: Market Share (%) by Region, 2021

For more details on this report - Request for Sample

Antibody Drug Conjugate Market Segment Analysis – By Product Type:

The Antibody Drug Conjugate Market based on product type can be further segmented into Adcetris, Kadcyla, and Others. The Kadcyla Segment held the largest market share in 2021. This growth is owing to the increasing application of KADCYLA as targeted therapy and prescription medication utilized as an adjuvant (consequent to surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (prior to surgery) treatment inclusive of a taxane and trastuzumab (Herceptin ®) and there is cancer remaining in the tissue eliminated at the time of surgery. The enhanced survival rate in HER2-positive patients is further propelling the growth of the Kadcyla segment.

Furthermore, the Adcetris segment is estimated to grow with the fastest CAGR of 15.4% during the forecast period 2022-2027 owing to the soaring application of Adcetris for newly diagnosed mature grown-ups with Stage 3 or 4 classical Hodgkin lymphoma as targeted therapy.

Antibody Drug Conjugate Market Segment Analysis – By Application:

The Antibody Drug Conjugate Market based on the application can be further segmented into Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others. The Breast Cancer Segment held the largest market share in 2021. This growth is owing to the increasing predominance of breast cancer worldwide. In the beginning, HER2-positive breast cancer was connected with a high rate of reoccurrence and reduced rate of survival. With the accessibility of trastuzumab and other particular HER2 antigen-targeted therapy, there have been enhanced results for this kind of cancer treatment. The surging R&D for breast cancer treatment and enhanced survival rate is further propelling the growth of this segment.

Furthermore, the Blood Cancer segment is estimated to grow with the fastest CAGR of 15.9% during the forecast period 2022-2027 owing to the raised pervasiveness of blood cancer and endorsement of antibody-drug conjugate medications and investigations through clinical trials in the treatment of blood cancer probably as targeted therapy.

Antibody Drug Conjugate Market Segment Analysis – By Geography:

The Antibody Drug Conjugate Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America (Antibody Drug Conjugate Market) held the largest share with 37% of the overall market in 2021. The growth of this region is owing to the extensive augmentation of ingenious technologies in U.S., Canada, and Mexico in the region. The soaring progress of clinical information and surging application of antibody-drug conjugates as a targeted therapy for cancer is further driving the growth of the Antibody Drug Conjugate Market in this region. The increasing predominance of breast cancer and the existence of superior healthcare infrastructure is further propelling the growth of the Antibody Drug Conjugate Market in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the sudden outbreak of the COVID-19 pandemic in the Wuhan province in China and further neighboring countries in the Asia-Pacific region. The enormous population and the emergence of distinct kinds of cancers requiring the application of targeted therapy are further fuelling the progress of the Antibody Drug Conjugate Market in the Asia-Pacific region.

Antibody Drug Conjugate Market Drivers

  • Surging Applications Of Monoclonal Antibodies Are Projected To Drive The Growth Of Antibody Drug Conjugate Market:

Monoclonal antibodies (mAbs) or monospecific antibodies are a class of antibodies secluded in the laboratory from a single clone of rare parent cells or a cell line. They include antibody molecules that are alike. Monoclonal antibodies have complicated secondary and tertiary structures.  These structures are exposed to post-translational alteration like protein glycosylation, a procedure that involves the inclusion of a carbohydrate moiety to a protein molecule.  This procedure assists in the proper folding of proteins, stability, and in cell to cell adhesion typically required by cells of the immune system. One of the benefits of monoclonal antibodies is that they are so particular that, unlike chemotherapy, mAb-based treatment may only have mild side effects.  A number of mAbs have been demonstrated to be more useful against cancer and, over the last two decades, the U.S. Food and Drug Administration (FDA) has endorsed around a dozen mAbs to treat some cancers. The surging applications of monoclonal antibodies are therefore fuelling the growth of the Antibody Drug Conjugate Market during the forecast period 2022-2027.

  • Novel Antibody-Based Immunotherapies For Cancer Immunotherapy Treatment Are Expected To Boost The Demand Of Antibody Drug Conjugate Market:

Antibody-drug conjugates or ADCs are a class of biopharmaceutical medications planned as a targeted therapy for treating cancer. Targeted antibodies are a kind of cancer immunotherapy treatment that can disorganize cancer cell activity and notify the immune system to aim and remove cancer cells. Currently, technological progress has allowed the establishment of novel antibody-based immunotherapies. One technique is antibody-drug conjugates (ADCs) in which a targeted antibody is outfitted with anti-cancer medications so that when the antibody aims and fastens to cancer cells, it also transfers a toxic medication that can destroy the cancer cells. By transferring these chemotherapeutic medications directly to tumors, it can possibly minimize the side effects related to the indiscriminate deployment of these toxic constituents. Another novel kind of antibody-based immunotherapy that has been developed is bispecific antibodies. These are prepared by taking the targeting front end regions of two distinct antibodies and integrating them to build a product that can fasten to two distinct targets. Certain bispecific antibodies termed bispecific T cell engagers, or BiTEs, aim at both cancer cells and immune cells termed T cells. These BiTEs perform to bring T cells into close proximity and allow them to remove cancer cells. Owing to their capability to aim immune cells directly, these BiTEs are regarded as “active” immunotherapies. The earliest bispecific antibody a BiTE termed blinatumomab (Blincyto® was endorsed by the FDA in 2014 for subsets of patients with leukemia. Additional bispecific antibodies have been established to aim for distinct cancer antigens. The emergence of novel antibody-based immunotherapies for cancer immunotherapy treatment is driving the growth of the Antibody Drug Conjugate Market during the forecast period 2022-2027.

Antibody Drug Conjugate Market Challenges

  • Antibody-Drug Conjugate Aggregation Is Hampering The Growth Of The Antibody Drug Conjugate Market:

Antibody Drug Conjugates are susceptible to aggregation. Antibody-Drug Conjugate aggregation is an impediment in the beginning phases in the establishment of an Antibody-Drug Conjugate. It brings about structural alteration which can block its fastening capability to the antigen. Apart from this, deterioration by aggregation demonstrates a principal challenge in terms of satisfying the guidelines for stability testing to acquire eligibility for registration of prescription medicine. Guidelines have been offered for this by the regulatory agencies like the Australian Therapeutic Goods Administration (TGA), European Medicines Agency (EMA), and U.S. Food And Drug Administration (FDA). This issue is thus hampering the growth of the Antibody Drug Conjugate Market.

Antibody Drug Conjugate Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Antibody Drug Conjugate Market. Key companies of this market are:

  1. Seagen Inc.
  2. ImmunoGen Inc.
  3. Mersana Therapeutics
  4. Pfizer Inc.
  5. F Hoffmann-La Roche Ltd
  6. Sorrento Therapeutics
  7. AbbVie Inc.
  8. Celldex Therapeutics
  9. Seattle Genetics
  10. Concortis Biotherapeutics

Recent Developments

  • In April 2021, Pfizer Inc. declared that it has gained Amplyx Pharmaceuticals, Inc., a privately-held firm committed to the establishment of therapies for draining and life-threatening ailments that influence people with jeopardized immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a new investigational asset under development for the treatment of invasive fungal contaminations. Over 1.5 million cases of invasive fungal contaminations happen globally every year, with mortality rates as huge as 30-80% across contamination kinds.
  • In March 2021, Roche declared the introduction of cobas pure integrated solutions in nations accepting the CE mark. This novel compact analyzer integrates three technologies on a single platform assisting to make everyday operations effortless in laboratories with reduced space and resources. Presently more than ever, diagnostic laboratories have proven to be a crucial constituent of the healthcare system worldwide.
  • In January 2021, Roche declared the CE-IVD introduction of its automatized digital pathology algorithms, uPath HER2 (4B5) image analysis, and uPath Dual ISH image analysis for breast cancer to assist in deciding the most excellent treatment strategy for every patient. The image analysis algorithms utilize artificial intelligence to back pathologists in making quicker, more precise patient diagnoses in breast cancer. A mutation in the HER2 gene, which happens in as many as 20 percent of the 2.1 million cases of breast cancer diagnosed worldwide every year, is accountable for intrusive development in certain patients.

Related Reports-

Antibody Testing Market – Forecast (2022 - 2027)

Report Code: HCR 1360

Immunohistochemistry Market – Forecast (2022 - 2027)

Report Code: HCR 0446

For more Lifesciences and Healthcare related reports, please click here

1. Antibody Drug Conjugate Market Overview
    1.1 Definitions and Scope
2. Antibody Drug Conjugate Market - Executive Summary
3. Antibody Drug Conjugate Market– Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Antibody Drug Conjugate Market– Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Antibody Drug Conjugate Market– Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Antibody Drug Conjugate Market- Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Antibody Drug Conjugate Market– By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Antibody Drug Conjugate Market - By Product Type (Market Size –$Million/$Billion) 
    8.1 Adcetris
    8.2 Kadcyla
    8.3 Others
9. Antibody Drug Conjugate Market – By Application (Market Size –$Million/$Billion) 
    9.1 Blood Cancer
    9.2 Breast Cancer
    9.3 Ovary Cancer
    9.4 Lung Cancer
    9.5 Skin Cancer
    9.6 Brain Tumor
    9.7 Others
10. Antibody Drug Conjugate Market- By Geography (Market Size -$Million/Billion)
    10.1 North America
        10.1.1 U.S
        10.1.2 Canada
        10.1.3 Mexico
    10.2 Europe
        10.2.1 Germany
        10.2.2 France
        10.2.3 UK
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Russia
        10.2.7 Rest of Europe
    10.3 Asia-Pacific
        10.3.1 China
        10.3.2 Japan
        10.3.3 South Korea
        10.3.4 India
        10.3.5 Australia & New Zealand
        10.3.6 Rest of Asia-Pacific
    10.4 South America
        10.4.1 Brazil
        10.4.2 Argentina
        10.4.3 Chile
        10.4.4 Colombia
        10.4.5 Rest of South America
    10.5 Rest Of The World
        10.5.1 Middle East
        10.5.2 Africa
11. Antibody Drug Conjugate Market- Market Entropy
    11.1 New product launches
    11.2 M&A's, collaborations, JVs, and partnerships
12. Antibody Drug Conjugate Market– Industry Competition Landscape (Premium)
    12.1 Market Share Analysis
        12.1.1 Global Market Share – Key Companies
        12.1.2 Market Share by Region – Key Companies
        12.1.3 Market Share by Countries – Key Companies
    12.2 Competition Matrix
    12.3 Best Practices for Companies
13. Antibody Drug Conjugate Market– Key Company List by Country Premium (Premium)
14. Antibody Drug Conjugate Market- Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"
List of Tables

Table 1: Antibody Drug Conjugate Market Overview 2021-2026
Table 2: Antibody Drug Conjugate Market Leader Analysis 2018-2019 (US$)
Table 3: Antibody Drug Conjugate Market Product Analysis 2018-2019 (US$)
Table 4: Antibody Drug Conjugate Market End User Analysis 2018-2019 (US$)
Table 5: Antibody Drug Conjugate Market Patent Analysis 2013-2018* (US$)
Table 6: Antibody Drug Conjugate Market Financial Analysis 2018-2019 (US$)
Table 7: Antibody Drug Conjugate Market Driver Analysis 2018-2019 (US$)
Table 8: Antibody Drug Conjugate Market Challenges Analysis 2018-2019 (US$)
Table 9: Antibody Drug Conjugate Market Constraint Analysis 2018-2019 (US$)
Table 10: Antibody Drug Conjugate Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Antibody Drug Conjugate Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Antibody Drug Conjugate Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Antibody Drug Conjugate Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Antibody Drug Conjugate Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Antibody Drug Conjugate Market Value Chain Analysis 2018-2019 (US$)
Table 16: Antibody Drug Conjugate Market Pricing Analysis 2021-2026 (US$)
Table 17: Antibody Drug Conjugate Market Opportunities Analysis 2021-2026 (US$)
Table 18: Antibody Drug Conjugate Market Product Life Cycle Analysis 2021-2026 (US$)
Table 19: Antibody Drug Conjugate Market Supplier Analysis 2018-2019 (US$)
Table 20: Antibody Drug Conjugate Market Distributor Analysis 2018-2019 (US$)
Table 21: Antibody Drug Conjugate Market Trend Analysis 2018-2019 (US$)
Table 22: Antibody Drug Conjugate Market Size 2018 (US$)
Table 23: Antibody Drug Conjugate Market Forecast Analysis 2021-2026 (US$)
Table 24: Antibody Drug Conjugate Market Sales Forecast Analysis 2021-2026 (Units)
Table 25: Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2021-2026 ($)
Table 26: Antibody Drug Conjugate Market By Phase, Revenue & Volume,By Clinical, 2021-2026 ($)
Table 27: Antibody Drug Conjugate Market By Phase, Revenue & Volume,By Pre-Clinical, 2021-2026 ($)
Table 28: Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2021-2026 ($)
Table 29: Antibody Drug Conjugate Market By Availability, Revenue & Volume,By Approved Drugs, 2021-2026 ($)
Table 30: Antibody Drug Conjugate Market By Availability, Revenue & Volume,By Pipeline Drugs, 2021-2026 ($)
Table 31: North America Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2021-2026 ($)
Table 32: North America Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2021-2026 ($)
Table 33: South america Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2021-2026 ($)
Table 34: South america Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2021-2026 ($)
Table 35: Europe Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2021-2026 ($)
Table 36: Europe Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2021-2026 ($)
Table 37: APAC Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2021-2026 ($)
Table 38: APAC Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2021-2026 ($)
Table 39: Middle East & Africa Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2021-2026 ($)
Table 40: Middle East & Africa Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2021-2026 ($)
Table 41: Russia Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2021-2026 ($)
Table 42: Russia Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2021-2026 ($)
Table 43: Israel Antibody Drug Conjugate Market, Revenue & Volume,By Phase, 2021-2026 ($)
Table 44: Israel Antibody Drug Conjugate Market, Revenue & Volume,By Availability, 2021-2026 ($)
Table 45: Top Companies 2018 (US$)Antibody Drug Conjugate Market, Revenue & Volume
Table 46: Product Launch 2018-2019Antibody Drug Conjugate Market, Revenue & Volume
Table 47: Mergers & Acquistions 2018-2019Antibody Drug Conjugate Market, Revenue & Volume


List of Figures

Figure 1: Overview of Antibody Drug Conjugate Market 2021-2026
Figure 2: Market Share Analysis for Antibody Drug Conjugate Market 2018 (US$)
Figure 3: Product Comparison in Antibody Drug Conjugate Market 2018-2019 (US$)
Figure 4: End User Profile for Antibody Drug Conjugate Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Antibody Drug Conjugate Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Antibody Drug Conjugate Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Antibody Drug Conjugate Market 2018-2019
Figure 8: Ecosystem Analysis in Antibody Drug Conjugate Market 2018
Figure 9: Average Selling Price in Antibody Drug Conjugate Market 2021-2026
Figure 10: Top Opportunites in Antibody Drug Conjugate Market 2018-2019
Figure 11: Market Life Cycle Analysis in Antibody Drug Conjugate Market
Figure 12: GlobalBy PhaseAntibody Drug Conjugate Market Revenue, 2021-2026 ($)
Figure 13: GlobalBy Availability Antibody Drug Conjugate Market Revenue, 2021-2026 ($)
Figure 14: Global Antibody Drug Conjugate Market - By Geography
Figure 15: Global Antibody Drug Conjugate Market Value & Volume, By Geography, 2021-2026 ($) 
Figure 16: Global Antibody Drug Conjugate Market CAGR, By Geography, 2021-2026 (%)
Figure 17: North America Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 18: US Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 19: US GDP and Population, 2018-2019 ($)
Figure 20: US GDP – Composition of 2018, By Sector of Origin
Figure 21: US Export and Import Value & Volume, 2018-2019 ($)
Figure 22: Canada Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 23: Canada GDP and Population, 2018-2019 ($)
Figure 24: Canada GDP – Composition of 2018, By Sector of Origin
Figure 25: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 26: Mexico Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 27: Mexico GDP and Population, 2018-2019 ($)
Figure 28: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 29: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 30: South America Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 31: Brazil Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 32: Brazil GDP and Population, 2018-2019 ($)
Figure 33: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 34: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 35: Venezuela Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 36: Venezuela GDP and Population, 2018-2019 ($)
Figure 37: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 38: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 39: Argentina Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 40: Argentina GDP and Population, 2018-2019 ($)
Figure 41: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 42: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 43: Ecuador Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 44: Ecuador GDP and Population, 2018-2019 ($)
Figure 45: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 46: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 47: Peru Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 48: Peru GDP and Population, 2018-2019 ($)
Figure 49: Peru GDP – Composition of 2018, By Sector of Origin
Figure 50: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 51: Colombia Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 52: Colombia GDP and Population, 2018-2019 ($)
Figure 53: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 54: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 55: Costa Rica Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 56: Costa Rica GDP and Population, 2018-2019 ($)
Figure 57: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 58: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 59: Europe Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 60: U.K Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 61: U.K GDP and Population, 2018-2019 ($)
Figure 62: U.K GDP – Composition of 2018, By Sector of Origin
Figure 63: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 64: Germany Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 65: Germany GDP and Population, 2018-2019 ($)
Figure 66: Germany GDP – Composition of 2018, By Sector of Origin
Figure 67: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 68: Italy Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 69: Italy GDP and Population, 2018-2019 ($)
Figure 70: Italy GDP – Composition of 2018, By Sector of Origin
Figure 71: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 72: France Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 73: France GDP and Population, 2018-2019 ($)
Figure 74: France GDP – Composition of 2018, By Sector of Origin
Figure 75: France Export and Import Value & Volume, 2018-2019 ($)
Figure 76: Netherlands Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 77: Netherlands GDP and Population, 2018-2019 ($)
Figure 78: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 79: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 80: Belgium Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 81: Belgium GDP and Population, 2018-2019 ($)
Figure 82: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 83: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 84: Spain Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 85: Spain GDP and Population, 2018-2019 ($)
Figure 86: Spain GDP – Composition of 2018, By Sector of Origin
Figure 87: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 88: Denmark Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 89: Denmark GDP and Population, 2018-2019 ($)
Figure 90: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 91: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 92: APAC Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 93: China Antibody Drug Conjugate Market Value & Volume, 2021-2026
Figure 94: China GDP and Population, 2018-2019 ($)
Figure 95: China GDP – Composition of 2018, By Sector of Origin
Figure 96: China Export and Import Value & Volume, 2018-2019 ($)Antibody Drug Conjugate Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 97: Australia Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 98: Australia GDP and Population, 2018-2019 ($)
Figure 99: Australia GDP – Composition of 2018, By Sector of Origin
Figure 100: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 101: South Korea Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 102: South Korea GDP and Population, 2018-2019 ($)
Figure 103: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 104: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 105: India Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 106: India GDP and Population, 2018-2019 ($)
Figure 107: India GDP – Composition of 2018, By Sector of Origin
Figure 108: India Export and Import Value & Volume, 2018-2019 ($)
Figure 109: Taiwan Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 110: Taiwan GDP and Population, 2018-2019 ($)
Figure 111: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 112: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 113: Malaysia Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 114: Malaysia GDP and Population, 2018-2019 ($)
Figure 115: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 116: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 117: Hong Kong Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 118: Hong Kong GDP and Population, 2018-2019 ($)
Figure 119: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 120: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 121: Middle East & Africa Antibody Drug Conjugate Market Middle East & Africa 3D Printing Market Value & Volume, 2021-2026 ($)
Figure 122: Russia Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 123: Russia GDP and Population, 2018-2019 ($)
Figure 124: Russia GDP – Composition of 2018, By Sector of Origin
Figure 125: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 126: Israel Antibody Drug Conjugate Market Value & Volume, 2021-2026 ($)
Figure 127: Israel GDP and Population, 2018-2019 ($)
Figure 128: Israel GDP – Composition of 2018, By Sector of Origin
Figure 129: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 130: Entropy Share, By Strategies, 2018-2019* (%)Antibody Drug Conjugate Market 
Figure 131: Developments, 2018-2019*Antibody Drug Conjugate Market 
Figure 132: Company 1 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 133: Company 1 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 134: Company 1 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 135: Company 2 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 136: Company 2 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 137: Company 2 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 138: Company 3Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 139: Company 3Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 140: Company 3Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 141: Company 4 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 142: Company 4 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 143: Company 4 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 144: Company 5 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 145: Company 5 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 146: Company 5 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 147: Company 6 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 148: Company 6 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 149: Company 6 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 150: Company 7 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 151: Company 7 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 152: Company 7 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 153: Company 8 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 154: Company 8 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 155: Company 8 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 156: Company 9 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 157: Company 9 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 158: Company 9 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 159: Company 10 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 160: Company 10 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 161: Company 10 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 162: Company 11 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 163: Company 11 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 164: Company 11 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 165: Company 12 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 166: Company 12 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 167: Company 12 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 168: Company 13Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 169: Company 13Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 170: Company 13Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 171: Company 14 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 172: Company 14 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 173: Company 14 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)
Figure 174: Company 15 Antibody Drug Conjugate Market Net Revenue, By Years, 2018-2019* ($)
Figure 175: Company 15 Antibody Drug Conjugate Market Net Revenue Share, By Business segments, 2018 (%)
Figure 176: Company 15 Antibody Drug Conjugate Market Net Sales Share, By Geography, 2018 (%)